



U.S. Food and Drug Administration

Notice: Archived Document

The content in this document is provided on the FDA's website for reference purposes only. It was current when produced, but is no longer maintained and may be outdated.



Center for Drug Evaluation and Research (CDER)



CAPT Mary E. Kremzner, USPHS
Deputy Director
Division of Drug Information
Center for Drug Evaluation and Research
Food and Drug Administration





Session Overview

- Federal Government Framework
- Drug Development Process
- Postmarketing Activities
- Generics
- Over-the-Counter Drugs
- Orphan Drugs



Food and Drug Administration

CDRH

NCTR

CBER

Center for Drug Evaluation
and Research

ORA


CTP

CFSAN

CVM

CDER

OFFICE OF REGULATORY AFFAIRS





FDA Mission

1. Promote public health
2. Protect public health
3. Participate with representatives of other countries to reduce the burden of regulation, harmonize regulatory requirements, and achieve appropriate reciprocal arrangements;
4. Carry out (1) through (3) in consultation with experts in science, medicine, and public health, and in cooperation with consumers, users, manufacturers, importers, packers, distributors and retailers of regulated products.

CDER Mission

Assuring that safe and effective drugs are available to the American People

Regulatory Authority

- CDER Regulates
 - Based on therapeutic health claim in the
 - application
 - label and packaging
 - Advertising (for prescription drugs)
- CDER **does not** regulate
 - The practice of medicine
 - Compounds that do not make a health claim





The Term Drug Means

(A) - articles recognized in the official United States Pharmacopoeia, official Homoeopathic Pharmacopoeia of the United States, or official National Formulary, or any supplement to any of them; and

(B) articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or other animals; and

(C) articles (other than food) intended to affect the structure or any function of the body of man or other animals;







PRE-CLINICAL RESEARCH

DISCOVERY/SCREENING

SYNTHESIS
AND
PURIFICATION









New Drug Application (NDA) or Biologic License Application (BLA) contains the following:

- **Pre-clinical studies**
- **Human clinical studies**
- **Manufacturing details**
- **Labeling**
- **Additional information**



Prescription Drug User Fee Act (PDUFA)

<http://www.fda.gov/oc/pdufa/default.htm>




- Permits CDER/CBER to charge pharmaceutical manufacturers a fee to review drug applications
- These fees provide appropriate resources to accelerate the review of applications
- Not the only source of funds for CDER/CBER

The Application Review Process in CDER

- Submitted to Central Document Room
 - paper or electronic
- Processed and sent to appropriate Review Division
- Priority status determined
 - Standard: 10 months
 - Priority: 6 months
 - try to determine at time of acknowledgement letter,
MUST be determined by filing date

Organizational Structure





Scientific Review Staff

Reviewers specialize in

- Clinical (M.D.)
- Pharmacology/Toxicology (Ph.D.)
- Regulatory Project Management (R.N., Pharm.D.,)
- Chemistry (Ph.D.)
- Clinical Pharmacology/Biopharmaceutics (Ph.D., Pharm.D.)
- Statistics (Ph.D.)
- Microbiology (Ph.D.)



The role of the Review Division

- Provide advice and guidance to regulated industry during drug development
- Signatory authority for regulatory decisions related to new (i.e., not generic) drugs
 - Working in conjunction with the other offices within CDER
- Establish policy and procedures governing the above



FDA


Evaluates
benefits/risks
for the
population

Provider

evaluates
benefits/risk
for a **patient**

Patient

evaluates
benefits/risks
in terms of
**personal
values**





Advisory Committees

- Panel of OUTSIDE experts
- Provide advice and opinions to the FDA drug review team
- FDA advisory committee Information:


<http://www.fda.gov/AdvisoryCommittees/default.htm>


NDA / BLA Review in CDER: The Final Action(s)

Complete Response (CR)




Approval (AP)





Office of Surveillance & Epidemiology

- Medication Error Prevention & Risk Management
- Pharmacovigilance & Epidemiology





Post-marketing surveillance

U.S. Department of Health and Human Services

MEDWATCH

The FDA Safety Information and
Adverse Event Reporting Program

For VOLUNTARY reporting of
adverse events and product problems

Page ___ of ___

Form Approved: OMB No. 0910-0291, Expires: 03/31/05
See OMB statement on reverse.

FDA USE ONLY	
Triage unit sequence #	

A. PATIENT INFORMATION			
1. Patient Identifier In confidence	2. Age at Time of Event: or _____ Date of Birth:	3. Sex <input type="checkbox"/> Female <input type="checkbox"/> Male	4. Weight ____ lbs or ____ kgs

B. ADVERSE EVENT OR PRODUCT PROBLEM	
1. <input type="checkbox"/> Adverse Event and/or <input type="checkbox"/> Product Problem (e.g., defects/malfunctions)	
2. Outcomes Attributed to Adverse Event (Check all that apply)	
<input type="checkbox"/> Death: _____ (mo/day/yr)	<input type="checkbox"/> Disability
<input type="checkbox"/> Life-threatening	<input type="checkbox"/> Congenital Anomaly
<input type="checkbox"/> Hospitalization - initial or prolonged	<input type="checkbox"/> Required Intervention to Prevent Permanent Impairment/Damage
<input type="checkbox"/> Other: _____	
3. Date of Event (mo/day/year)	4. Date of This Report (mo/day/year)

5. Describe Event or Problem


C. SUSPECT MEDICATION(S)	
1. Name (Give labeled strength & mfr/labeler, if known)	
#1 _____	
#2 _____	
2. Dose, Frequency & Route Used	3. Therapy Dates (If unknown, give duration from/to (or best estimate))
#1 _____	#1 _____
#2 _____	#2 _____
4. Diagnosis for Use (Indication)	5. Event Abated After Use Stopped or Dose Reduced?
#1 _____	#1 <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Doesn't Apply
#2 _____	#2 <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Doesn't Apply
6. Lot # (if known)	7. Exp. Date (if known)
#1 _____	#1 _____
#2 _____	#2 _____
9. NDC# (For product problems only)	8. Event Reappeared After Reintroduction?
- -	#1 <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Doesn't Apply
	#2 <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Doesn't Apply
10. Concomitant Medical Products and Therapy Dates (Exclude treatment of event)	

- Limited power of Phase 3 trials to detect rare events
 - Rule of 3 – To detect event with incidence of 1/1000, need 3000 patients
 - Restricted patient population in clinical trials
- Passive voluntary reporting via Medwatch ----- most events not reported (numerator)
 - total exposure not known (denominator)
- Post-marketing events reported to manufacturer or directly to FDA

INK

Active Postmarket Risk Identification

- Active adverse event surveillance using Medicare and VA databases,
- Private sector electronic data
- Goal: system to include 100 million by 2012



Enhanced Authority Over Postmarket Safety of Drugs

**Under the FDA
Amendments Act FDA
now can require:**

- Post approval studies
- Labeling changes
- Establish enforceable timelines





DDMAC

Division of Drug Marketing Advertising and Communications

Promotion of Prescription Drug Products

- Promotional Materials Review Guidance and policy development
- Research
- Surveillance and enforcement




Office of Compliance

- Sets labeling, manufacturing, and testing standards
- Monitors the quality of marketed drugs
- Evaluates, classifies, and recommends a course of action

Compliance – Unapproved Drugs Initiative


Focused efforts on:

- Classes of unapproved drugs
- Firms marketing unapproved drugs
- Using a risk based approach for enforcement actions





Generic Drug Review Process





OTC Drug Review Process

FDA reviews active ingredients and finds they are safe and effective

Prescription to OTC Switch

The drug company submits a supplement to the new drug application NDA to “switch to OTC

New OTC drug

The sponsor/manufacturer submits a new drug application NDA as an OTC drug

Orphan Drugs

- For Rare Diseases and Conditions
 - Less than 200,000 persons
 - No expectation of development cost recovery
- Incentives
 - 7 years market exclusivity (vs. 5 years)
 - Tax credit for clinical research
- Designation
 - Administered by Office of Orphan Products Development
 - Does not alter the standard review requirements



Questions?





DDI Contact Information

Telephone - 1-888.INFO.FDA (463-6332) or
301-796-3400

Web-Site - <http://www.fda.gov/AboutDDI>

Email - druginfo@fda.hhs.gov

Mail - 10001 New Hampshire Ave.
Hillandale Building, 4th Floor
Silver Spring, MD 20993

Follow us on Twitter: FDA_Drug_Info

Sign up for the DDI Listserv on our website





CDER Small Business Contact

Telephone – 1.866.405.5367 or
301.796.6707

Web-Site - <http://www.fda.gov/smallbusinessdrugs>

Email – CDERSmallBusiness@fda.hhs.gov

Mail - 10001 New Hampshire Ave.
Hillandale Building, 4th Floor
Silver Spring, MD 20993 -0002



- **Sign up for the CDER Small Business Listserv on our website**
- **Download our Widget from website**